Drug intelligence / Profile preview

Cp-CAP

Development stage: Unknown
Lead developer: lege artis Pharma
Modality: Small Molecules
Administration: Dental Use

Overview

Cp-CAP is a dental medical device developed by lege artis Pharma GmbH + Co. KG, specifically designed for use in prosthetic dentistry and dental restoration. It is a zinc oxide eugenol cement enriched with calcium hydroxide, provided as a two-component system consisting of a powder and a solution for individual mixing. The product is primarily indicated for direct and indirect pulp capping to maintain the vitality of endangered dental pulp and for the attachment of temporary restorations. Its formulation leverages the sedative properties of eugenol and the dentin-stimulating effects of calcium hydroxide to prevent pulpitic discomfort following tooth preparation. Additionally, Cp-CAP is slightly radiopaque, allowing for visibility on X-rays during follow-up procedures.

Brand names: Cp-CAP

Beyond the preview

Go deeper on Cp-CAP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cp-CAP.

Explore the full profile